CY1111355T1 - Μειωση της ζαλης, μια παρενεργεια που συσχετιζεται με την θεραπεια πιρφενιδονης - Google Patents

Μειωση της ζαλης, μια παρενεργεια που συσχετιζεται με την θεραπεια πιρφενιδονης

Info

Publication number
CY1111355T1
CY1111355T1 CY20111100306T CY111100306T CY1111355T1 CY 1111355 T1 CY1111355 T1 CY 1111355T1 CY 20111100306 T CY20111100306 T CY 20111100306T CY 111100306 T CY111100306 T CY 111100306T CY 1111355 T1 CY1111355 T1 CY 1111355T1
Authority
CY
Cyprus
Prior art keywords
dizziness
decrease
side effect
pirfenidone
effect associated
Prior art date
Application number
CY20111100306T
Other languages
Greek (el)
English (en)
Inventor
Cynthia Y Robinson
Jeffery Stuart Loutit
Michelle M Freemer
Original Assignee
Intermune, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37807840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111355(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune, Inc. filed Critical Intermune, Inc.
Publication of CY1111355T1 publication Critical patent/CY1111355T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Husbandry (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
CY20111100306T 2005-12-02 2011-03-21 Μειωση της ζαλης, μια παρενεργεια που συσχετιζεται με την θεραπεια πιρφενιδονης CY1111355T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74197605P 2005-12-02 2005-12-02
EP06838621A EP1965797B1 (en) 2005-12-02 2006-11-29 Reduction of dizziness, a side effect associated with pirfenidone therapy

Publications (1)

Publication Number Publication Date
CY1111355T1 true CY1111355T1 (el) 2015-08-05

Family

ID=37807840

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100306T CY1111355T1 (el) 2005-12-02 2011-03-21 Μειωση της ζαλης, μια παρενεργεια που συσχετιζεται με την θεραπεια πιρφενιδονης

Country Status (13)

Country Link
US (1) US20070203202A1 (enExample)
EP (2) EP1965797B1 (enExample)
JP (3) JP5175740B2 (enExample)
AT (1) ATE497766T1 (enExample)
CA (1) CA2631646C (enExample)
CY (1) CY1111355T1 (enExample)
DE (1) DE602006020070D1 (enExample)
DK (1) DK1965797T3 (enExample)
ES (2) ES2385935T3 (enExample)
PL (1) PL1965797T3 (enExample)
PT (1) PT1965797E (enExample)
SI (1) SI1965797T1 (enExample)
WO (1) WO2007064738A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070203202A1 (en) 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy
CA2667654C (en) * 2006-12-18 2016-12-13 Intermune, Inc. Method of providing pirfenidone therapy to a patient
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
AU2008265595B2 (en) 2007-06-20 2014-12-04 PureTech LYT 100 Inc. Substituted N-Aryl pyridinones as fibrotic inhibitors
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US7566729B1 (en) 2008-11-10 2009-07-28 Intermune, Inc. Modifying pirfenidone treatment for patients with atypical liver function
EP2389227A4 (en) * 2009-01-26 2012-08-08 Intermune Inc METHOD FOR THE TREATMENT OF ACUTE MYOCARDINE CARDS AND ASSOCIATED ILLNESSES THEREOF
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
HUE058753T2 (hu) 2011-01-31 2022-09-28 Avalyn Pharma Inc Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
BR112013022766A2 (pt) * 2011-03-08 2016-12-06 Auspex Pharmaceuticals Inc método de administração de d-pirfenidona e kit
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
JP5872564B2 (ja) * 2011-09-14 2016-03-01 塩野義製薬株式会社 吸入用医薬組成物
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
EP2968292A4 (en) 2013-03-15 2016-11-23 Intermune Inc METHOD FOR IMPROVING MICROVASCULAR INTEGRITY
JP7066321B2 (ja) 2014-01-10 2022-05-13 アヴァリン ファーマ インク． エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
WO2021107060A1 (ja) * 2019-11-27 2021-06-03 塩野義製薬株式会社 ピルフェニドンの副作用を軽減するための医薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839346A (en) * 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
DE60234812D1 (de) * 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
US20070032457A1 (en) * 2003-05-16 2007-02-08 Blatt Lawrence M Combination therapy for cancer treatment
US20070203202A1 (en) 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy

Also Published As

Publication number Publication date
JP2012229275A (ja) 2012-11-22
JP2015061888A (ja) 2015-04-02
DE602006020070D1 (de) 2011-03-24
JP2009518293A (ja) 2009-05-07
EP1965797A1 (en) 2008-09-10
EP2316453B1 (en) 2016-01-06
WO2007064738A1 (en) 2007-06-07
CA2631646C (en) 2016-07-26
PT1965797E (pt) 2011-05-12
SI1965797T1 (sl) 2011-03-31
HK1123213A1 (en) 2009-06-12
EP1965797B1 (en) 2011-02-09
ES2385935T3 (es) 2012-08-03
CA2631646A1 (en) 2007-06-07
ATE497766T1 (de) 2011-02-15
DK1965797T3 (da) 2011-05-02
EP2316453A1 (en) 2011-05-04
JP5175740B2 (ja) 2013-04-03
ES2565190T3 (es) 2016-04-01
PL1965797T3 (pl) 2011-07-29
US20070203202A1 (en) 2007-08-30
HK1151726A1 (en) 2012-02-10

Similar Documents

Publication Publication Date Title
DK1965797T3 (da) Nedsættelse af svimmelhed, en bivirkning forbundet med pirfenidonterapi
WO2006119958A3 (en) Use of flibanserin in the treatment of chronic pain
UA88464C2 (ru) Способ дермального введения метадоновой композиции с обеспечением системного действия
WO2004075832A3 (en) Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
MX2009006007A (es) Profarmacos y metodos para hacer y usar los mismos.
WO2009002867A3 (en) Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
GEP20135803B (en) Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
CY1112478T1 (el) Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
DK2043637T3 (da) Fremgangsmåder og medikamenter til administrering af ibuprofen
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
MX344476B (es) Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal.
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
TN2010000135A1 (en) Galenical formulations of organic compounds
WO2005081742A3 (en) Testosterone oral dosage formulations and associated methods
MX2009011900A (es) Curacion de herida diabetica.
SE0400184D0 (sv) New therapeutical use
WO2006119389A3 (en) Quinine-containing controlled-release formulations
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
ATE540690T1 (de) Insulinkombinationen
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno
BRPI0510820A (pt) composição farmacêutica, forma unitária de dosagem e seus usos
WO2007144889A3 (en) Treatment of neurofibromatosis
SE0203817D0 (sv) New composition